In this regard, gefitinib or trastuzumab could restore tamoxifen’s anti-tumour effects in MCR7/HER2-18 cells, whereas it had only a modest effect on the inhibition of oestrogen-stimulated growth (Shou et al. 2004). The gene discussed is ERBB2; the disease is neoplasm.